The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Chemical Aspects of Selective Toxicity
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1945) · Harvard University Press eBooks · doi:10.4159/harvard.9780674184220 · Cited by 1,078
The Permeability of Natural Membranes
(1944) · Annals of the Entomological Society of America · doi:10.1093/aesa/37.1.83 · Cited by 720
The use of chemical potentials as indices of toxicity
Ferguson, J. (1939) · Proceedings of the Royal Society of London. Series B - Biological Sciences · doi:10.1098/rspb.1939.0030 · Cited by 558
Cullen, S. C., & Gross, E. G. (1951) · Science · doi:10.1126/science.113.2942.580 · Cited by 460
PERMEABILITY OF NATURAL MEMBRANES
Danielli, J. F. (1953) · The Lancet · doi:10.1016/s0140-6736(53)91792-9 · Cited by 424
Some Physico-Chemical Factors in Drug Action
Brodie, B. B., & Hogben, C. A. M. (1957) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1957.tb12289.x · Cited by 396
Detoxication of Drugs and Other Foreign Compounds by Liver Microsomes
Brodie, B. B., Axelrod, J., Cooper, J. R., Gaudette, L., La Du, B. N., Mitoma, C., & Udenfriend, S. (1955) · Science · doi:10.1126/science.121.3147.603 · Cited by 261
The Specificity of Serological Reactions.
(1963) · Annals of Internal Medicine · doi:10.7326/0003-4819-59-2-263_4 · Cited by 242
(1903) · Nature · doi:10.1038/068547a0 · Cited by 197
Woolley, D. W. (1952) · Andalas University Repository (Andalas University) · Cited by 133
Cited by
The expanding role of prodrugs in contemporary drug design and development
Rautio, J., Meanwell, N. A., Di, L., & Hageman, M. J. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.46 · Cited by 767
Role of Pharmacokinetics and Metabolism in Drug Discovery and Development
Lin, J. H., & Lu, A. Y. H. (1997) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01340-1 · Cited by 708
Intranasal Drug Delivery: How, Why and What For?
Pires, A., Fortuna, A., Alves, G., & Falcão, A. (2009) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3nc79 · Cited by 641
Prodrugs—from Serendipity to Rational Design
Huttunen, K. M., Raunio, H., & Rautio, J. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003459 · Cited by 505
Enzyme-Catalyzed Activation of Anticancer Prodrugs
Rooseboom, M., Commandeur, J. N. M., & Vermeulen, N. P. E. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.1.3 · Cited by 497
Recent Advances in the Application of Vitamin E TPGS for Drug Delivery
Yang, C., Wu, T., Qi, Y., & Zhang, Z. (2018) · Theranostics · doi:10.7150/thno.22711 · Cited by 402
Lessons Learned from Marketed and Investigational Prodrugs
Ettmayer, P., Amidon, G. L., Clement, B., & Testa, B. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0303812 · Cited by 384
Enzymes involved in the bioconversion of ester-based prodrugs
Liederer, B. M., & Borchardt, R. T. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20542 · Cited by 377
Cheetham, A. G., Chakroun, R. W., Ma, W., & Cui, H. (2017) · Chem. Soc. Rev. · doi:10.1039/c7cs00521k · Cited by 367
Current approaches to enhance CNS delivery of drugs across the brain barriers
Lu, C.-T., Zhao, Y.-Z., Wong, H. L., Cai, J., Peng, L., & Tian, X.-Q. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s61288 · Cited by 350
Recent trends in the design of anticancer polymer prodrug nanocarriers
Delplace, V., Couvreur, P., & Nicolas, J. (2014) · Polym. Chem. · doi:10.1039/c3py01384g · Cited by 287
Polymorphic Cytochrome P450 Enzymes (CYPs) and Their Role in Personalized Therapy
Preissner, S. C., Hoffmann, M. F., Preissner, R., Dunkel, M., Gewiess, A., & Preissner, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082562 · Cited by 278
Targeted prodrug design to optimize drug delivery
Han, H.-K., & Amidon, G. L. (2000) · AAPS PharmSci · doi:10.1208/ps020106 · Cited by 277
5‐Aminolevulinic Acid Derivatives in Photomedicine: Characteristics, Application and Perspectives
Fotinos, N., Campo, M. A., Popowycz, F., Gurny, R., & Lange, N. (2006) · Photochemistry and Photobiology · doi:10.1562/2006-02-03-ir-794 · Cited by 238
“According to Albert (6) a prodrug is a nonactive compound that, after administration, is metabolically converted to a pharmacologically active compound.”
BackgroundEvolution of the treatment of attention-deficit/hyperactivity disorder in children: A review
Findling, R. L. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.05.006 · Cited by 129
Nanoscale Mixed-Ligand Metal–Organic Framework for X-ray Stimulated Cancer Therapy
Zhen, W., Xu, Z., Mao, Y., McCleary, C., Jiang, X., Weichselbaum, R. R., & Lin, W. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c12140 · Cited by 37
Self-immolative Linkers in Prodrugs and Antibody Drug Conjugates in Cancer Treatment
Edupuganti, V. V. S. R., Tyndall, J. D. A., & Gamble, A. B. (2021) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892816666210509001139 · Cited by 36
“4 Prodrugs In 1958, Adrien Albert introduced the term “prodrug” [11] meaning any compound that undergoes biotransformation before showing its pharmacological effects.”
BackgroundLisdexamfetamine dimesylate: the first prodrug stimulant.
(2007) · PubMed Central · Cited by 24
Metadata
- Authors
- ALBERT, A.
- Venue
- Nature
- Published
- 1958-08
- Volume
- 182
- Issue
- 4633
- Pages
- 421-423
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2065452150
- Cited by
- 401
- References
- 15
- FWCI
- 2.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.